Results 191 to 200 of about 92,043 (285)

Integrative genomic and functional characterization of ADAMTS3 reveals its inflammatory regulation via NF‐κB and STAT3 pathways in osteosarcoma

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Abstract Osteosarcoma (OS) is an aggressive bone malignancy characterized by genomic instability and extensive extracellular matrix (ECM) remodeling. Members of the ADAMTS family are matrix‐associated proteases implicated in tumorigenesis; however, their roles in OS remain poorly defined. This study provides a comprehensive genomic, transcriptomic, and
Ehed Muhammed Aymaz, Meltem Alper, Feyza Nur Sav, Tuğşen Aydemir, Feray Köçkar   +4 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Management of Severe Behçet's Disease. [PDF]

Curr Rheumatol Rep
Abacar K, Direskeneli H, Alibaz-Oner F.
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Bilateral Renal Artery Thrombosis in a Patient With Behçet's Disease Managed With Infliximab Infusions. [PDF]

Cureus
Akcan OE, Yilmaz S.
europepmc   +1 more source

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yoshihide Ueda, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +53 more
wiley   +1 more source

Revisiting <i>HLA-DQA1</i>*05 in Asian inflammatory bowel disease cohorts: Ethnic variations in genetic susceptibility to immunogenicity. [PDF]

World J Gastroenterol
Hu CQ, Song XM, Teng YS, Guo H.
europepmc   +1 more source

Neutrophil‐to‐Lymphocyte Ratio as a Predictor of Cardiovascular Events in Psoriatic Disease: A Retrospective Cohort Study

ACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective The aim of this study was to evaluate the neutrophil‐to‐lymphocyte ratio (NLR) as an independent predictor of major adverse cardiovascular events (MACEs) and all‐cause mortality in patients with psoriasis (PsO) or psoriatic arthritis (PsA). Methods We conducted a retrospective cohort study of 967 patients (825 with PsO and 142 with PsA) at a ...
Mauro Martini, Luciano Logiudice, Luis D. Mazzuoccolo, Nicolas Alvarado, Alfredo Vargas Caselles, Paola De La Torre, Valentina Torres Londono, Maria Laura Acosta Felquer, Javier Rosa, Enrique R. Soriano   +9 more
wiley   +1 more source

Immediate and delayed hypersensitivity to biologicals in children-A practical approach: An EAACI task force report. [PDF]

Pediatr Allergy Immunol
Mori F, Atanaskovic-Markovic M, Barbaud A, Bavbek S, Caubet JC, de Las Vecillas L, Giovannini M, Khaleva E, Labella M, Moral L, Riggioni C, Sabato V, Tsabouri S, Arasi S.   +13 more
europepmc   +1 more source

The Immune Landscape of Acral Melanoma: From Basic to Clinical

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
Lihong Jiang, Zhaotian Zhang
wiley   +1 more source